Sumatriptan succinate and Injection site haemorrhage - a phase IV clinical study of FDA data

Summary:

Injection site haemorrhage is reported as a side effect among people who take Sumatriptan succinate (sumatriptan succinate), especially for people who are female, 50-59 old, have been taking the drug for < 1 month also take Imitrex, and have Psoriatic arthropathy.

The phase IV clinical study analyzes which people have Injection site haemorrhage when taking Sumatriptan succinate. It is created by eHealthMe based on reports of 9,380 people who have side effects when taking Sumatriptan succinate from the FDA, and is updated regularly.

What is Sumatriptan succinate?

Sumatriptan succinate has active ingredients of sumatriptan succinate. It is often used in migraine. eHealthMe is studying from 9,731 Sumatriptan succinate users. Check the latest studies of Sumatriptan succinate.

What is Injection site haemorrhage?

Injection site haemorrhage (bleeding from injection site) is found to be associated with 1,123 drugs and 1,133 conditions by eHealthMe. Check the latest studies of Injection site haemorrhage.

On Jul, 18, 2026

9,380 people reported to have side effects when taking Sumatriptan succinate.
Among them, 65 people (0.69%) have Injection site haemorrhage.

Could Sumatriptan succinate cause Injection site haemorrhage?

Among these 65 people:

How long have people been on Sumatriptan succinate when they have Injection site haemorrhage? *

What is the gender of people who have Injection site haemorrhage when taking Sumatriptan succinate? *

female: 98.28 %
male: 1.72 %

What is the age of people who have Injection site haemorrhage when taking Sumatriptan succinate? *

What are other drugs people take besides Sumatriptan succinate? *

What are other side effects people have besides Injection site haemorrhage? *

Injection Site Pain: 20 people, 30.77%
Injection Site Bruising: 16 people, 24.62%
Weight Decreased: 9 people, 13.85%
Cough: 9 people, 13.85%
Neck Pain: 8 people, 12.31%
Abdominal Pain: 8 people, 12.31%
Back Pain: 8 people, 12.31%
Dysmenorrhea (painful menstruation): 8 people, 12.31%
Hair Loss: 8 people, 12.31%
Itching: 8 people, 12.31%

What are the existing conditions these people have? *

Psoriatic Arthropathy (inflammation of the skin and joints with kin condition which typically causes patches (plaques) of red, scaly skin to develop): 5 people, 7.69%
Immunodeficiency Common Variable: 4 people, 6.15%
Multiple Sclerosis (a nervous system disease that affects your brain and spinal cord. it damages the myelin sheath): 2 people, 3.08%
Headache (pain in head): 2 people, 3.08%
Rheumatoid Arthritis (a chronic progressive disease causing inflammation in the joints): 1 person, 1.54%
Pain: 1 person, 1.54%
Depression: 1 person, 1.54%

* Approximation only. Some reports may have incomplete information.

Do you take Sumatriptan succinate and have Injection site haemorrhage?

- Check whether Injection site haemorrhage is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Sumatriptan succinate:

Sumatriptan succinate (9,731 reports)

Browse all side effects of Sumatriptan succinate:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Injection site haemorrhage:

Injection site haemorrhage (1,123 drugs)

Browse all the conditions that are associated with Injection site haemorrhage:

Injection site haemorrhage (1,133 conditions)

How the study uses the data?

The study uses data from the FDA. It is based on sumatriptan succinate (the active ingredients of Sumatriptan succinate) and Sumatriptan succinate (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.